We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Gritstone bio Inc | NASDAQ:GRTS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0027 | -0.28% | 0.96 | 0.9584 | 0.9616 | 0.97 | 0.9229 | 0.963 | 1,084,837 | 20:40:40 |
As filed with the Securities and Exchange Commission on May 9, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Gritstone bio, Inc.
(Exact name of Registrant as specified in its charter)
Delaware | 47-4859534 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) | |
5959 Horton Street, Suite 300 Emeryville, California 94608 |
94608 | |
(Address of Principal Executive Offices) | (Zip Code) |
2021 Employment Inducement Incentive Plan
(Full Title of the Plan)
Andrew Allen, M.D., Ph.D.
President and Chief Executive Officer
Gritstone bio, Inc.
5959 Horton Street, Suite 300
Emeryville, California 94608
(510) 871-6100
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Brian J. Cuneo, Esq.
Latham & Watkins LLP
140 Scott Drive
Menlo Park, California 94025
Telephone: (650) 328-4600
Facsimile: (650) 463-2600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☒ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are exercised and/or vest.
REGISTRATION OF ADDITIONAL SECURITIES
By a registration statement on Form S-8 filed with the Securities and Exchange Commission (the SEC) on May 6, 2021 (File No. 333-255847) (the Original Registration Statement), Gritstone bio, Inc. (the Registrant) registered 790,400 shares of common stock, par value $0.0001 per share (the Common Stock), issuable under the 2021 Employment Inducement Incentive Plan (the 2021 Plan). The Registrant is hereby registering an additional 700,000 shares of Common Stock issuable under the 2021 Plan which shares are now available for grant.
INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENT ON FORM S-8
Pursuant to Instruction E of Form S-8, the contents of the Original Registration Statement are incorporated by reference in this registration statement on Form S-8.
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.
Item 8. Exhibits.
# | Indicates management contract or compensatory plan. |
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Emeryville, California, on this 9th day of May, 2022.
Gritstone bio, Inc. | ||
By: | /s/ Andrew Allen | |
Andrew Allen, M.D., Ph.D. | ||
President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Andrew Allen, M.D., Ph.D., Vassiliki Economides and Rahsaan Thompson and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.
Signature |
Title |
Date | ||
/s/ Andrew Allen |
President, Chief Executive Officer and Director | May 9, 2022 | ||
Andrew Allen, M.D., Ph.D. | (Principal Executive Officer) | |||
/s/ Vassiliki Economides |
Chief Financial Officer | May 9, 2022 | ||
Vassiliki Economides | (Principal Financial Officer) | |||
/s/ James Cho |
Chief Accounting Officer | May 9, 2022 | ||
James Cho | (Principal Accounting Officer) | |||
/s/ Elaine Jones |
Chairperson of Our Board of Directors | May 9, 2022 | ||
Elaine Jones, Ph.D. | ||||
/s/ Clare Fisher |
Director | May 9, 2022 | ||
Clare Fisher | ||||
/s/ Steve Krognes |
Director | May 9, 2022 | ||
Steve Krognes | ||||
/s/ Naiyer A. Rizvi |
Director | May 9, 2022 | ||
Naiyer A. Rizvi, M.D. | ||||
/s/ Richard Heyman |
Director | May 9, 2022 | ||
Richard A. Heyman, Ph.D. | ||||
/s/ Shefali Agarwal |
Director | May 9, 2022 | ||
Shefali Agarwal, M.D., M.P.H. |
1 Year Gritstone bio Chart |
1 Month Gritstone bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions